Cargando…

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

Detalles Bibliográficos
Autores principales:	Mascarenhas, John, Harrison, Claire, Kiladjian, Jean-Jacques, Sockel, Katja, Vannucchi, Alessandro, Berry, Tymara, Redding, Denise, Sherman, Laurie, Dougherty, Souria, Peng, Lixian, Sun, Libo, Huang, Fei, Wan, Ying, Rodolf, Vivian, Ho, Judy, Navada, Shyamala, Komrokji, Rami S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429542/ http://dx.doi.org/10.1097/01.HS9.0000975644.99899.f4

Ejemplares similares

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
por: Kuykendall, Andrew, et al.
Publicado: (2023)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
por: Mascarenhas, J., et al.
Publicado: (2022)

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Santini, Valeria, et al.
Publicado: (2023)

P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS
por: Sekeres, Mikkael, et al.
Publicado: (2023)

PB2225: ENVIRONMENTAL MODIFIERS OF SEVERITY IN CHILDREN WITH SICKLE CELL DISEASE: A FEASIBILITY PILOT STUDY
por: Strouse, J., et al.
Publicado: (2022)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Biological drivers of clinical phenotype in myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2022)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
por: Huang, J., et al.
Publicado: (2022)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023)

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
por: Riazat-Kesh, Yosef Joseph Rene Amel, et al.
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS
por: Junker, Sophia, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
por: Leibundgut, Elisabeth Oppliger, et al.
Publicado: (2020)

PB2055: A RARE CASE OF HIGH-RISK HEREDITARY THROMBOPHILIA COMBINED WITH PRIMARY MYELOFIBROSIS
por: Khoduleva, S., et al.
Publicado: (2022)

PB2166: PRIMARY MYELOFIBROSIS: SERUM LACTATE DEHYDROGENASE AS A PREDICTOR OF EARLY LEUKEMIC PROGRESSION
por: Moura, Pedro, et al.
Publicado: (2023)

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
por: Bonuomo, Valentina, et al.
Publicado: (2023)

PB2228: WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?
por: Moura, Pedro, et al.
Publicado: (2023)

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
por: Tefferi, A, et al.
Publicado: (2016)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION
por: Perolla, A., et al.
Publicado: (2022)

PB2196: CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY
por: Malchiodi, Margherita, et al.
Publicado: (2023)

PB2251: SOMETIMES IT’S ZEBRAS: SUCCESSFUL TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA POST PRIMARY MYELOFIBROSIS WITH GIVOSIRAN - A CASE REPORT
por: Catana, Alina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ljfdinca06uhlqoejvdv1e2ou2